- **Faruqi & Faruqi, LLP** is investigating **Unicycive Therapeutics** for potential federal securities law violations, alleging the company made false or misleading statements regarding its readiness to satisfy **FDA** manufacturing compliance requirements and the regulatory prospects of its **OLC NDA**.  **[1766140_ac2fc027e79d4b4589e363ac2f134e09_1]** 
- The investigation stems from two significant stock price drops: on **June 10, 2025**, the stock fell **$3.68 per share**, or **40.89%**, to **$5.32 per share** after the **FDA** identified manufacturing deficiencies, and on **June 30, 2025**, it fell an additional **$2.03 per share**, or **29.85%**, to **$4.77 per share** following a **Complete Response Letter** for the **OLC NDA** due to the same issues.  **[1766140_ac2fc027e79d4b4589e363ac2f134e09_1]** 
- Investors who purchased or acquired **Unicycive** securities between **March 29, 2024, and June 27, 2025**, may be affected, and the deadline to seek the role of lead plaintiff in the federal securities class action is **October 14, 2025**.  **[1766140_ac2fc027e79d4b4589e363ac2f134e09_0]** **[1766140_ac2fc027e79d4b4589e363ac2f134e09_1]**

Faruqi & Faruqi Investigates Unicycive Therapeutics for Securities Violations

- Bragar Eagel & Squire, P.C. has commenced a class action lawsuit against Unicycive (NASDAQ:UNCY) on behalf of stockholders.  **[1766140_ebdc8d0b64024bd198141e6676661952_0]** 
- The class period for the lawsuit is **March 29, 2024, through June 27, 2025**, with a lead plaintiff deadline of **October 14, 2025**.  **[1766140_ebdc8d0b64024bd198141e6676661952_0]** 
- The complaint alleges that Unicycive overstated its readiness and ability to satisfy the U.S. Food and Drug Administration's (FDA) manufacturing compliance requirements for its oxylanthanum carbonate (OLC) New Drug Application (NDA).  **[1766140_ebdc8d0b64024bd198141e6676661952_0]** 
- On **June 10, 2025**, Unicycive announced the FDA identified deficiencies in cGMP compliance at a third-party manufacturing vendor, causing the stock price to fall **over 40%**.  **[1766140_ebdc8d0b64024bd198141e6676661952_0]** 
- On **June 30, 2025**, the FDA issued a Complete Response Letter for the OLC NDA, citing the previously identified cGMP deficiencies, which led to an almost **30%** stock price drop, closing at **$4.77 per share**.  **[1766140_ebdc8d0b64024bd198141e6676661952_0]**

Unicycive Therapeutics (UNCY)